Clinical Trial: Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV
Brief Summary: A single arm phase 2 study to study the outcome of dose-escalation with simultaneous integrated boost to intraprostatic lesion and positive lymph nodes. Prostate cancer patients with high risk of lymph node metastasis or oligo positive nodes in true pelvic area can be included. The boost volumes will be outlined by usin PET-CT and MRI data. Our hypothesis is that we will have fewer relapses in this very high risk patient group compared to matched historical controls with acceptable side effects.
Detailed Summary:
Sponsor: Umeå University
Current Primary Outcome: PSA progression free survival [ Time Frame: 36 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Quality of Life [ Time Frame: 0,6,12,36,60 months ]
Original Secondary Outcome: Same as current
Information By: Umeå University
Dates:
Date Received: October 9, 2013
Date Started: March 2015
Date Completion: November 2022
Last Updated: October 26, 2016
Last Verified: October 2016